Rucaparib effective as maintenance therapy following first-line platinum-based chemo in ovarian ... скачать в хорошем качестве

Rucaparib effective as maintenance therapy following first-line platinum-based chemo in ovarian ...

Dr Bradley Monk speaks to ecancer about the ATHENA–MONO trial. This was a randomised, double-blind, phase 3 trial evaluating rucaparib monotherapy versus placebo as maintenance treatment following response to first-line platinum-based chemotherapy in ovarian cancer. Dr Monk says that the ATHENA trial was designed to test if rucaparib may be effective as 1L maintenance treatment in a broad patient population, including those without BRCA mutations or other evidence of homologous recombination deficiency (HRD), or high-risk clinical characteristics such as residual disease. The trial reported results from the ATHENA–MONO comparison of rucaparib vs placebo. Dr Monk then explains the trial design. He explains the results of the trial saying that rucaparib monotherapy is effective as 1L maintenance with significant benefit vs placebo observed in the ITT and HRD populations, as well as the non-nested subgroup of patients without known HRD.